Who Prioritizes Innovation? R&D Spending Compared for Teva Pharmaceutical Industries Limited and Jazz Pharmaceuticals plc

Teva vs. Jazz: A Decade of R&D Investment Trends

__timestampJazz Pharmaceuticals plcTeva Pharmaceutical Industries Limited
Wednesday, January 1, 2014851810001488000000
Thursday, January 1, 20151352530001525000000
Friday, January 1, 20161622970002111000000
Sunday, January 1, 20171984420001848000000
Monday, January 1, 20182266160001213000000
Tuesday, January 1, 20192997260001010000000
Wednesday, January 1, 2020335375000997000000
Friday, January 1, 2021505748000967000000
Saturday, January 1, 2022590453000838000000
Sunday, January 1, 2023849658000953000000
Monday, January 1, 2024998000000
Loading chart...

Igniting the spark of knowledge

Innovation in Pharmaceuticals: A Comparative Analysis

In the ever-evolving pharmaceutical industry, innovation is the key to staying ahead. Over the past decade, Teva Pharmaceutical Industries Limited and Jazz Pharmaceuticals plc have demonstrated contrasting approaches to research and development (R&D) spending. From 2014 to 2023, Teva consistently invested more in R&D, peaking in 2016 with a 2.1 billion USD expenditure. However, Jazz Pharmaceuticals has shown a remarkable growth trajectory, increasing its R&D spending by nearly 900% from 2014 to 2023. This surge reflects Jazz's commitment to innovation, closing the gap with Teva, whose R&D spending decreased by about 36% over the same period. As the pharmaceutical landscape continues to shift, these trends highlight the strategic priorities of each company, with Jazz emerging as a dynamic player in the race for innovation.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025